Stay updated on Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Sign up to get notified when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.

Latest updates to the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page
- ChecktodayChange DetectedThe site footer revision identifier changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check7 days agoChange DetectedThe clinical trial record for the REACH3 study is displayed, including its study design, eligibility criteria, treatment arms, outcomes, locations, publications, and study documents.SummaryDifference100%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedA site-wide NIH notice was added, announcing a website transition and stating that some NIH content will use “Super Intelligence” in place of “Artificial Intelligence.”SummaryDifference1%

- Check35 days agoChange DetectedThe error page footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.2%

- Check42 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1. The study page still displays a 403 Forbidden error.SummaryDifference0.2%

Stay in the know with updates to Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.